Treatment of early Parkinson's disease

Neurology

Volumn 58, Issue 4 SUPPL. 1, 2002, Pages

  Koller, William C ^a  

^a National Parkinson Foundation Inc   (United States)

Author keywords

Dopamine agonists; Neuroprotection; Parkinson's disease

Indexed keywords

AMANTADINE; AMGEN 474; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; APOPTOSIS INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTAMATE RECEPTOR ANTAGONIST; LEVODOPA; NEUROPROTECTIVE AGENT; NEUROTROPHIC FACTOR; PERGOLIDE; PRAMIPEXOLE; REMACEMIDE; RILUZOLE; ROPINIROLE; SELEGILINE; UBIDECARENONE; UNCLASSIFIED DRUG; ANTIPARKINSON AGENT;

AGE; APOPTOSIS; CLINICAL PROTOCOL; CLINICAL RESEARCH; COGNITION; CONTROLLED RELEASE FORMULATION; DRUG CHOICE; DRUG COST; DRUG MECHANISM; DRUG RESEARCH; DYSKINESIA; ENVIRONMENTAL FACTOR; EXERCISE; FAMILY THERAPY; GENETIC MANIPULATION; HUMAN; MOTOR DYSFUNCTION; NEUROPROTECTION; NUTRITION; PALLIATIVE THERAPY; PARKINSON DISEASE; PATHOPHYSIOLOGY; PATIENT EDUCATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; REVIEW; SUPPORT GROUP;

ANTIPARKINSON AGENTS; DOPAMINE AGONISTS; HUMANS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE;

EID: 0037176897     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.58.suppl_1.s79     Document Type: Review

References (36)

1. An algorithm (decision tree) for the management of Parkinson's disease (2001): Treatment guidelines
2. Living with a person who has Parkinson's disease: The spouse's perspective by stage of disease
3. Psychological distress, caregiving, and metabolic variables
4. Health maintenance behaviors in advanced Parkinson's disease
5. Alzheimer's disease support groups: An analysis of their structure, format, and perceived benefits
6. Exercise
7. Weight change and body composition in patients with Parkinson's disease
8. The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport
9. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease
10. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
11. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis
12. Understanding cell death in Parkinson's disease
13. Dopaminergic neurons degenerate by apoptosis in Parkinson's disease
14. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism
15. 123I Beta-CIT: Assessment of progression in Parkinson's disease
16. Effect of deprenyl on the progression of disability in early Parkinson's disease
17. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease
18. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease
19. The impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP, subjects not requiring levodopa
20. Treatment of Parkinson's disease
21. The spectrum of levodopa-related fluctuations in Parkinson's disease
22. Is levodopa toxic?
23. Levodopa in the treatment of Parkinson's disease: A consensus meeting
24. Chronic low-dose levodopa therapy in Parkison's disease: An argument for delaying levodopa therapy
25. Low-dose L-dopa therapy in Parkinson's disease: A 6-year follow-up study
26. The Sydney Multicentre Study of Parkinson's disease: A randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa
27. A randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease: A five-year follow up
28. Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients
29. Immediate-release and controlled-release carbidopa/levodopa in PD: A 5-year randomized multicenter study
30. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa
31. Pramipexole vs levodopa as initial treatment of Parkinson disease: A randomized controlled trial
32. Young onset Parkinson's disease
33. Preventing levodopa induced dyskinesias
34. Chronic treatment with L-dopa, but not bromocriptine induces dyskinesia in MPTP parkinsonian monkeys. Correlation with [3H]spiperone binding
35. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset
36. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complication. Results of a double-blind levodopa controlled trial